These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1516 related items for PubMed ID: 26984450

  • 1. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [Abstract] [Full Text] [Related]

  • 2. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [Abstract] [Full Text] [Related]

  • 3. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
    Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM.
    JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
    [Abstract] [Full Text] [Related]

  • 4. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E.
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [Abstract] [Full Text] [Related]

  • 5. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F, Barac A, Tan MT, Asch FM, Smith KL, Dang C, Isaacs C, Swain SM.
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [Abstract] [Full Text] [Related]

  • 6. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
    Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C, BERENICE Study Group.
    Ann Oncol; 2018 Mar 01; 29(3):646-653. PubMed ID: 29253081
    [Abstract] [Full Text] [Related]

  • 7. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R, Smyth LM, Iyengar N, Chandarlapaty S, Modi S, Jochelson M, Patil S, Norton L, Hudis CA, Dang CT.
    Oncologist; 2019 Aug 01; 24(8):e646-e652. PubMed ID: 30602614
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.
    Tryfonidis K, Marreaud S, Khaled H, De Valk B, Vermorken J, Welnicka-Jaskiewicz M, Aalders K, Bartlett JMS, Biganzoli L, Bogaerts J, Cameron D, EORTC- Breast Cancer Group.
    Breast Cancer Res Treat; 2017 Jun 01; 163(3):507-515. PubMed ID: 28324265
    [Abstract] [Full Text] [Related]

  • 10. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, CLEOPATRA study group.
    Lancet Oncol; 2020 Apr 01; 21(4):519-530. PubMed ID: 32171426
    [Abstract] [Full Text] [Related]

  • 11. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
    van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS, Dutch Breast Cancer Research Group (BOOG).
    Breast; 2016 Oct 01; 29():153-9. PubMed ID: 27498129
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA, Aksoy S, Yorgun H, Ozdemir N, Yilmaz FM, Yazıcı O, Zungun C, Aytemir K, Zengin N, Altundag K.
    Curr Med Res Opin; 2015 Mar 01; 31(3):547-56. PubMed ID: 25586297
    [Abstract] [Full Text] [Related]

  • 13. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
    Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Dan Costa S, Gerber B, Engels K, Nekljudova V, von Minckwitz G, Untch M, investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) study groups.
    Ann Oncol; 2017 Mar 01; 28(3):497-504. PubMed ID: 27831502
    [Abstract] [Full Text] [Related]

  • 14. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S, Khanfir A.
    Am J Clin Oncol; 2020 Jul 01; 43(7):510-516. PubMed ID: 32304433
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
    Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortés J.
    Eur J Cancer; 2018 Jan 01; 89():27-35. PubMed ID: 29223479
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS, Dutch Breast Cancer Research Group (BOOG).
    Lancet Oncol; 2018 Dec 01; 19(12):1630-1640. PubMed ID: 30413379
    [Abstract] [Full Text] [Related]

  • 17. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA.
    Breast Cancer Res Treat; 2012 Jul 01; 134(1):291-8. PubMed ID: 22476854
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
    Cheng S, Wang J, Wang Y, Qi L, Li F, Liu J, Chen J, Fan Y, Xie L.
    Eur Radiol Exp; 2023 May 15; 7(1):22. PubMed ID: 37183212
    [Abstract] [Full Text] [Related]

  • 19. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
    Woodward N, De Boer RH, Redfern A, White M, Young J, Truman M, Beith J.
    Clin Breast Cancer; 2019 Jun 15; 19(3):216-224. PubMed ID: 30922805
    [Abstract] [Full Text] [Related]

  • 20. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA, Aksoy S, Altundag K.
    Curr Med Res Opin; 2013 Aug 15; 29(8):1015-24. PubMed ID: 23692263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.